What is TACE?
TACE is a catheter-based treatment used mainly for selected liver tumours, particularly hepatocellular carcinoma. A catheter is advanced into the arteries feeding the tumour and chemotherapy with embolic material is delivered directly into the tumour circulation.
Who may benefit?
Suitability depends on tumour type, size, number and distribution, liver function, portal vein status, overall performance status and whether surgery, ablation or transplantation is appropriate.
How is the procedure planned?
Pre-procedure imaging such as multiphasic CT or MRI is reviewed carefully to map tumour burden and arterial anatomy.
What happens after treatment?
Some patients experience pain, fever, nausea or fatigue after embolisation. Blood tests and follow-up imaging are used to assess liver function and treatment response.
Is one session always enough?
No. Some patients require staged or repeat embolisation depending on tumour response and residual viable disease.
Frequently asked questions
Is TACE a cure for liver cancer?
Not always. In many patients it is used for disease control, downstaging or bridging, while in others it can be part of a combined treatment strategy.
Can TACE be combined with ablation or systemic therapy?
Yes. Multidisciplinary treatment plans may combine catheter-based therapy with ablation, surgery, transplantation or systemic treatment depending on the case.
Does every liver tumour need embolisation?
No. Treatment is selected after careful review of tumour biology, imaging, liver function and other available options.